Ref Type | Journal Article |
PMID | (20372153) |
Authors | Handolias D, Hamilton AL, Salemi R, Tan A, Moodie K, Kerr L, Dobrovic A, McArthur GA |
Title | Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. |
Journal | British journal of cancer |
Vol | 102 |
Issue | 8 |
Date | 2010 Apr 13 |
URL | |
Abstract Text | Mutations in KIT are more frequent in specific melanoma subtypes, and response to KIT inhibition is likely to depend on the identified mutation.A total of 32 patients with metastatic acral or mucosal melanoma were screened for mutations in KIT exons 11, 13 and 17.KIT mutations were found in 38% of mucosal and in 6% of acral melanomas. Three patients were treated with imatinib and one with sorafenib. All four patients responded to treatment, but three have since progressed within the brain.The observed clinical responses support further investigation of KIT inhibitors in metastatic melanoma, selected according to KIT mutation status. |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Therapy Description |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | KIT K642E | vulvar melanoma | predicted - sensitive | Imatinib | Clinical Study | Actionable | In a clinical case report, Gleevec (imatinib mesylate) treatment resulted in partial response in a patient with recurrent vulval melanoma harboring KIT K642E, reduced tumor mass by 35% (PMID: 20372153). | 20372153 | KIT exon 11 | melanoma | predicted - sensitive | Imatinib | Clinical Study | Actionable | In a clinical case report, Gleevec (imatinib mesylate) treatment resulted in partial response in a patient with metastasized anal melanoma harboring a 21 base-pair duplication in exon 11 of KIT, reduced pulmonary metastasis by 60% (PMID: 20372153). | 20372153 | KIT D820Y | melanoma | predicted - sensitive | Sorafenib | Clinical Study | Actionable | In a clinical case report, Nexavar (sorafenib) treatment resulted in stable disease in a patient with anal melanoma and pulmonary metastases harboring KIT D820Y (PMID: 20372153). | 20372153 | KIT L576P | melanoma | no benefit | Imatinib | Clinical Study | Actionable | In a clinical case report, Gleevec (imatinib mesylate) treatment resulted in initial tumor reduction followed by disease progression in a patient with metastasized labial melanoma harboring KIT L576P (PMID: 20372153). | 20372153 |
---|